Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The decision to initiate optional Part B in WHO Group 3 PH-ILD participants will be made by the Safety Review Committee (SRC).”In the company’s words, NCT06846554 on ClinicalTrials.gov
- Tested for
- Pulmonary Arterial Hypertension
- Main trialPhase 2
- “The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH. The study will also assess how effective APL-9796 could be for treating patients with PH and whether the body produces antibodies working against APL-9796. The trial will be conducted in two parts: * Part A: Up to 36 adults with WHO Group 1 Pulmonary arterial hypertension (PAH). * Part B (optional): Up to 12 adults with WHO Group 3 - PH associated with ILD (PH-ILD).”In the company’s words, NCT06846554 on ClinicalTrials.gov
Other drugs for Pulmonary Arterial Hypertension
- RalinepagUnited Therapeutics · Phase 3
- SeralutinibGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 3
- Treprostinil PalmitilInsmed Incorporated · Phase 3
- MacitentanActelion · Phase 3
- Macitentan/Tadalafil FDCActelion · Phase 3
- SelexipagActelion · Phase 3
Coming up1
- 30 Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Aug 2027 | A Trial of "APL-9796'' in Adults With Pulmonary Hypertension |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026